Trial Profile
Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Trabectedin (Primary)
- Indications Leiomyosarcoma; Soft tissue sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms LMS04
- 24 Oct 2023 Updated PFS results and final results of overall survival (OS) analyses (planned when all patients had at least 3 years of follow-up in patients with metastatic or unresectable leiomyosarcoma, presented at the 48th European Society for Medical Oncology Congress.
- 11 Jul 2022 Primary endpoint has been met (Primary Outcome Measures:Progression free Survival), as per Results published in the Lancet Oncology
- 11 Jul 2022 Results published in the Lancet Oncology